Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Assessment of the Concentration of Transforming Growth Factor Beta 1-3 in Degenerated Intervertebral Discs of the Lumbosacral Region of the Spine

R. Staszkiewicz, D. Gładysz, D. Sobański, F. Bolechała, E. Golec, M. Sobańska, D. Strojny, A. Turek, BO. Grabarek

. 2024 ; 46 (11) : 12813-12829. [pub] 20241111

Status not-indexed Language English Country Switzerland

Document type Journal Article

The purpose of this study was to evaluate the feasibility of using the expression profile of transforming growth factor beta (TGF-β-1-3) to assess the progression of L/S spine degenerative disease. The study group consisted of 113 lumbosacral (L/S) intervertebral disc (IVD) degenerative disease patients from whom IVDs were collected during a microdiscectomy, whereas the control group consisted of 81 participants from whom IVDs were collected during a forensic autopsy or organ harvesting. Hematoxylin and eosin staining was performed to exclude degenerative changes in the IVDs collected from the control group. The molecular analysis consisted of reverse-transcription real-time quantitative polymerase chain reaction (RT-qPCR), an enzyme-linked immunosorbent assay (ELISA), Western blotting, and an immunohistochemical analysis (IHC). In degenerated IVDs, we noted an overexpression of all TGF-β-1-3 mRNA isoforms with the largest changes observed for TGF-β3 isoforms (fold change (FC) = 19.52 ± 2.87) and the smallest for TGF-β2 (FC = 2.26 ± 0.16). Changes in the transcriptional activity of TGF-β-1-3 were statistically significant (p < 0.05). Significantly higher concentrations of TGF-β1 (2797 ± 132 pg/mL vs. 276 ± 19 pg/mL; p < 0.05), TGF-β2 (1918 ± 176 pg/mL vs. 159 ± 17 pg/mL; p < 0.05), and TGF-β3 (2573 ± 102 pg/mL vs. 152 ± 11 pg/mL) were observed in degenerative IVDs compared with the control samples. Determining the concentration profiles of TGF-β1-3 appears to be a promising monitoring tool for the progression of degenerative disease as well as for evaluating its treatment or developing new treatment strategies with molecular targets.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002160
003      
CZ-PrNML
005      
20250123102008.0
007      
ta
008      
250117s2024 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cimb46110763 $2 doi
035    __
$a (PubMed)39590357
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Staszkiewicz, Rafał $u Collegium Medicum, WSB University, 41-300 Dabrowa Gornicza, Poland $u Department of Neurosurgery, 5th Military Clinical Hospital with the SP ZOZ Polyclinic in Krakow, 30-901 Cracow, Poland $u Department of Neurosurgery, Faculty of Medicine in Zabrze, Academy of Silesia, 40-555 Katowice, Poland $1 https://orcid.org/0000000207816534
245    10
$a Assessment of the Concentration of Transforming Growth Factor Beta 1-3 in Degenerated Intervertebral Discs of the Lumbosacral Region of the Spine / $c R. Staszkiewicz, D. Gładysz, D. Sobański, F. Bolechała, E. Golec, M. Sobańska, D. Strojny, A. Turek, BO. Grabarek
520    9_
$a The purpose of this study was to evaluate the feasibility of using the expression profile of transforming growth factor beta (TGF-β-1-3) to assess the progression of L/S spine degenerative disease. The study group consisted of 113 lumbosacral (L/S) intervertebral disc (IVD) degenerative disease patients from whom IVDs were collected during a microdiscectomy, whereas the control group consisted of 81 participants from whom IVDs were collected during a forensic autopsy or organ harvesting. Hematoxylin and eosin staining was performed to exclude degenerative changes in the IVDs collected from the control group. The molecular analysis consisted of reverse-transcription real-time quantitative polymerase chain reaction (RT-qPCR), an enzyme-linked immunosorbent assay (ELISA), Western blotting, and an immunohistochemical analysis (IHC). In degenerated IVDs, we noted an overexpression of all TGF-β-1-3 mRNA isoforms with the largest changes observed for TGF-β3 isoforms (fold change (FC) = 19.52 ± 2.87) and the smallest for TGF-β2 (FC = 2.26 ± 0.16). Changes in the transcriptional activity of TGF-β-1-3 were statistically significant (p < 0.05). Significantly higher concentrations of TGF-β1 (2797 ± 132 pg/mL vs. 276 ± 19 pg/mL; p < 0.05), TGF-β2 (1918 ± 176 pg/mL vs. 159 ± 17 pg/mL; p < 0.05), and TGF-β3 (2573 ± 102 pg/mL vs. 152 ± 11 pg/mL) were observed in degenerative IVDs compared with the control samples. Determining the concentration profiles of TGF-β1-3 appears to be a promising monitoring tool for the progression of degenerative disease as well as for evaluating its treatment or developing new treatment strategies with molecular targets.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Gładysz, Dorian $u Department of Neurosurgery, 5th Military Clinical Hospital with the SP ZOZ Polyclinic in Krakow, 30-901 Cracow, Poland $u Department of Neurosurgery, Faculty of Medicine in Zabrze, Academy of Silesia, 40-555 Katowice, Poland
700    1_
$a Sobański, Dawid $u Collegium Medicum, WSB University, 41-300 Dabrowa Gornicza, Poland $u Department of Neurosurgery, Szpital sw. Rafala in Cracow, 30-693 Cracow, Poland $1 https://orcid.org/0000000255256201
700    1_
$a Bolechała, Filip $u Department of Forensic Medicine, Jagiellonian University Medical College, 31-531 Cracow, Poland
700    1_
$a Golec, Edward $u Department of Rehabilitation in Orthopaedics, Faculty of Motor Rehabilitation, Bronisław Czech University of Physical Education, 31-571 Krakow, Poland
700    1_
$a Sobańska, Małgorzata $u Collegium Medicum, WSB University, 41-300 Dabrowa Gornicza, Poland $u Department of Neurosurgery, Szpital sw. Rafala in Cracow, 30-693 Cracow, Poland
700    1_
$a Strojny, Damian $u Collegium Medicum, WSB University, 41-300 Dabrowa Gornicza, Poland $u Institute of Health Care, National Academy of Applied Sciences in Przemyśl, 37-700 Przemyśl, Poland $u New Medical Techniques Specjalist Hospital of St. Family in Rudna Mała, 36-060 Rzeszów, Poland $1 https://orcid.org/0009000723243039
700    1_
$a Turek, Artur $u Chair and Department of Biopharmacy, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Katowice, 41-200 Sosnowiec, Poland $1 https://orcid.org/0000000201172985
700    1_
$a Grabarek, Beniamin Oskar $u Collegium Medicum, WSB University, 41-300 Dabrowa Gornicza, Poland $u Department of Molecular Biology, Gyncentrum, Laboratory of Molecular Biology and Virology, 40-851 Katowice, Poland $1 https://orcid.org/0000000316337145
773    0_
$w MED00173547 $t Current issues in molecular biology $x 1467-3045 $g Roč. 46, č. 11 (2024), s. 12813-12829
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39590357 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250117 $b ABA008
991    __
$a 20250123102002 $b ABA008
999    __
$a ok $b bmc $g 2254489 $s 1238163
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 46 $c 11 $d 12813-12829 $e 20241111 $i 1467-3045 $m Current issues in molecular biology $n Curr Issues Mol Biol $x MED00173547
LZP    __
$a Pubmed-20250117

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...